PARAMOUNT+ SETS MARCH 6 NORTH AMERICAN PREMIERE FOR AWARD-WINNING DOCUMENTARY THE PINK PILL: SEX, DRUGS & WHO HAS CONTROL

Rhea-AI Summary

Paramount+ (PSKY) will premiere the documentary THE PINK PILL: SEX, DRUGS & WHO HAS CONTROL in North America on March 6, 2026, ahead of International Women’s Day.

Directed by Aisling Chin-Yee, the film examines the cultural, scientific and political fight around Addyi, the FDA- and Health Canada-approved treatment for hypoactive sexual desire disorder, and spotlights entrepreneur Cindy Eckert and Docs for Change collaborators.

News Market Reaction

-6.90%

1 alert

-6.90% News Effect

On the day this news was published, PSKY declined 6.90%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Premiere date: March 6 International Women’s Day: March 8 Initial FDA approval year: 2015 +3 more

6 metrics

Premiere date March 6 North American premiere on Paramount+ in Canada and the U.S.

International Women’s Day March 8 Premiere timed ahead of International Women’s Day (March 8).

Initial FDA approval year 2015 FDA approval of Addyi for HSDD in premenopausal women in 2015.

Age limit for indication Under 65 FDA expanded Addyi approval to include postmenopausal women under 65.

Knix history 13 years Knix founder notes the brand was founded 13 years ago.

Audience Award 1 award Documentary received the Audience Award at DOC NYC.

Market Reality Check

Price: $10.32 Vol: Volume 6,916,346 is close...

normal vol

$10.32 Last Close

Volume Volume 6,916,346 is close to 20-day average 7,119,041 (relative volume 0.97x). normal

Technical Trading below 200-day MA, with price at $11.01 versus 200-day MA of $14.81.

Peers on Argus

PSKY is up 1.57% while key peers like WMG (-3.22%), NWS (-1.96%), NWSA (-1.15%),...

PSKY is up 1.57% while key peers like WMG (-3.22%), NWS (-1.96%), NWSA (-1.15%), TKO (-2.23%) and FWONA (-0.28%) are down, indicating stock-specific strength rather than a sector move.

Historical Context

5 past events · Latest: Feb 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Tender offer response	Positive	+1.5%	WBD confirms receipt of amended unsolicited tender offer from Paramount Skydance.
Feb 10	Enhanced acquisition bid	Positive	+1.5%	Paramount enhances all-cash <b>$30</b> per share offer and details financing.
Feb 04	Earnings date notice	Neutral	-2.1%	Company schedules Q4 and full-year 2025 results call for Feb 25, 2026.
Jan 29	Dividend declaration	Positive	-0.7%	Board declares <b>$0.05</b> per share quarterly cash dividend for April 1, 2026.
Jan 22	Proxy and tender update	Positive	+1.6%	Paramount files proxy materials and extends tender offer related to WBD bid.

Pattern Detected

Recent news has focused on the WBD tender offer, proxy actions, dividends and upcoming earnings, with mostly modest positive reactions but occasional selloffs even on shareholder-friendly items like dividends.

Recent Company History

Over the past few weeks, Paramount Skydance has centered news flow on its all-cash $30.00 per share offer for Warner Bros. Discovery and related proxy efforts, alongside routine items like a $0.05 quarterly dividend and scheduling its Feb 25, 2026 earnings release. These events produced mixed but generally modest price moves, suggesting investors are closely tracking strategic M&A developments. Today’s documentary premiere announcement adds a brand and content narrative alongside the ongoing large-scale transaction story.

Market Pulse Summary

The stock moved -6.9% in the session following this news. A negative reaction despite this brand- an...

Analysis

The stock moved -6.9% in the session following this news. A negative reaction despite this brand- and content-focused announcement would contrast with the modest 1.57% pre-news gain and the stock’s position below its 200-day MA at $11.01 versus $14.81. Past news tied to strategic initiatives and dividends has sometimes seen weakness, such as after the $0.05 dividend declaration. Any sharp decline would likely be interpreted against that backdrop of mixed responses to company updates and ongoing M&A-related uncertainty.

Key Terms

food and drug administration (fda), health canada, hypoactive sexual desire disorder (hsdd), premenopausal, +1 more

5 terms

food and drug administration (fda) regulatory

"the first United States Food and Drug Administration (FDA) and Health Canada-approved"

A U.S. government agency that reviews and approves drugs, medical devices, vaccines, food safety measures and related products before they reach the market. Think of it as a gatekeeper whose decisions, inspections and safety warnings can make or break a product’s ability to sell; investors watch FDA actions closely because approvals speed revenue and failed reviews, delays or recalls can sharply change a company’s value.

health canada regulatory

"Food and Drug Administration (FDA) and Health Canada-approved treatment for women's sexual desire."

Health Canada is the government department responsible for overseeing the safety and regulation of health-related products and services in Canada, including medications, medical devices, and vaccines. Its approval and guidelines help ensure that these products are safe and effective for public use. For investors, Health Canada's decisions can influence the success of healthcare companies and affect the availability of new medical treatments in the Canadian market.

hypoactive sexual desire disorder (hsdd) medical

"approval for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in 2015."

Hypoactive sexual desire disorder (HSDD) is a medical condition marked by a persistent or recurring lack of sexual desire that causes significant personal distress and is not explained by other medical, psychiatric, or relationship problems. It matters to investors because it defines an addressable patient population for therapies and influences clinical trial design, regulatory approval, insurance coverage, and commercial potential—think of it like a clearly identified customer need that determines whether a treatment can succeed in the market.

premenopausal medical

"for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in 2015."

Premenopausal describes the phase in a person's life before menopause, when natural menstrual cycles and reproductive hormones are still active. For investors, it signals a distinct patient or consumer group with specific healthcare needs—such as contraception, fertility care, hormone treatments and related testing—similar to how a particular customer segment shapes demand for certain products; understanding its size and characteristics helps forecast markets and regulatory or clinical trial impacts.

postmenopausal medical

"expanded its approval to include postmenopausal women under 65."

A postmenopausal person is someone who has gone through menopause and has not had a menstrual period for 12 consecutive months, reflecting the natural end of reproductive hormone cycling. For investors, this designation matters because it defines a specific patient market and regulatory group for drugs, devices and health services—similar to identifying a customer segment by age or lifecycle stage—affecting demand forecasts, clinical trial design and approval pathways.

AI-generated analysis. Not financial advice.

Directed By Award-Winning Montreal Filmmaker Aisling Chin-Yee, The Film Ignites A Global Conversation On Women's Health, Power, And Medical Equity Ahead Of International Women's Day 

Trailer for THE PINK PILL: SEX, DRUGS & WHO HAS CONTROL now available HERE
Link to Images HERE 

TORONTO, Feb. 12, 2026 /PRNewswire/ -- Paramount+ announced today that breakout documentary THE PINK PILL: SEX, DRUGS & WHO HAS CONTROL will premiere in Canada and the U.S. on March 6, ahead of International Women's Day (March 8). Celebrating powerful storytelling about women by women, the bold and boundary-pushing film examines the cultural, scientific, and political battle behind the first United States Food and Drug Administration (FDA) and Health Canada-approved treatment for women's sexual desire. 

At its center is Cindy Eckert, entrepreneur and women's health advocate, whose trademark pink and fearless determination made her a lightning rod in the battle to bring Addyi— which the media dubbed "female Viagra"—to market. Eckert confronted gender bias head-on, ultimately winning approval for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in 2015. This past December, the FDA expanded its approval to include postmenopausal women under 65. 

The Paramount+ Original THE PINK PILL is directed by award-winning Canadian filmmaker Aisling Chin-Yee (No Ordinary Man, The Rest of Us, Plan B) and produced by Catalyst and Everywoman Studios. Executive Producers are Julie Bristow (Catalyst), Abby Greensfelder (Everywoman Studios), Vibika Bianchi, Aisling Chin-Yee and Joanna Griffiths (Knix). Writers are Chin-Yee and Steve Taylor, who also serves as editor. Director of Photography is Nina Djacic. The film marks the first project from Docs for Change, a collaboration between Catalyst, the Toronto-based studio for woman-identifying creators, and Knix Fund, a philanthropic arm of the game-changing intimates brand Knix. 

"Medical sexism knows no borders," said Chin-Yee. "As a Canadian filmmaker, I had the opportunity to shine a rare spotlight on desire, the reclamation of pleasure, and bodily autonomy. This film confronts both cultural and institutional gender bias. My hope is that it sparks meaningful conversations and momentum around how our health is valued and prioritized."

"THE PINK PILL: SEX, DRUGS & WHO HAS CONTROL" has already drawn widespread critical praise. DOC NYC, where the film premiered last fall, hailed it as "witty, urgent, and illuminating" and awarded the film the Audience Award, underscoring how deeply this subject matter resonates with audiences. The Alliance of Women Film Journalists called it "an engaging, educational documentary with a lot of interesting layers," while ArtsFuse noted that "the film's brazen, Barbie-ized motif sets it apart in the grey solemnity of documentaries." To date, the documentary has received coverage in The New York Times, People, ELLE, Fast Company, and more.

"Being a part of this film is exactly why I founded Knix 13 years ago – to connect with women from all different walks of life and start conversations that make an impact," said Griffiths. "We want our customers to know we are advocating for them, and we are thrilled to bring this project to the masses." 

About Paramount, a Skydance Corporation
Paramount, a Skydance Corporation (Nasdaq: PSKY) is a leading, next‑generation global media and entertainment company, comprised of three business segments: Studios, Direct-to-Consumer, and TV Media. The Company's portfolio unites legendary brands, including Paramount Pictures, Paramount Television, CBS – America's most-watched broadcast network, CBS News, CBS Sports, Nickelodeon, MTV, BET, Comedy Central, SHOWTIME^®, Paramount+, Pluto TV, and Skydance's Animation, Film, Television, Interactive/Games, and Sports divisions. For more information, please visit www.paramount.com.

Follow @thepinkpillfilm on Instagram and visit www.thepinkpillfilm.com for the latest news, exclusive content and more. For more information about Paramount+, please visit www.paramountplus.com and follow @ParamountPlusCA on social media.

@ThePinkPillFilm
@ParamountPlusCA

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/paramount-sets-march-6-north-american-premiere-for-award-winning-documentary-the-pink-pill-sex-drugs--who-has-control-302685943.html

SOURCE Paramount+ (Canada)

FAQ

When will Paramount+ (PSKY) premiere THE PINK PILL documentary in North America?

The documentary premieres on March 6, 2026 in Canada and the U.S. According to Paramount+, the release precedes International Women’s Day and follows festival screenings that earned critical praise.

What is THE PINK PILL about and who directed it for Paramount+ (PSKY)?

The film explores the cultural and regulatory battle over women’s sexual health treatments. According to Paramount+, it is directed by Canadian filmmaker Aisling Chin-Yee and centers on entrepreneur Cindy Eckert and Addyi’s story.

Does THE PINK PILL discuss regulatory approvals for Addyi on Paramount+ (PSKY)?

Yes. The film highlights Addyi’s FDA approval for premenopausal women and an FDA expansion to include postmenopausal women under 65. According to Paramount+, it examines related scientific and political debates.

Which producers and partners are credited on Paramount+ (PSKY) for THE PINK PILL?

The film is produced by Catalyst and Everywoman Studios with executive producers including Julie Bristow and Joanna Griffiths. According to Paramount+, Docs for Change and Knix Fund are collaborators on the project.

Has THE PINK PILL received critical recognition before the Paramount+ (PSKY) premiere?

Yes. The film won the DOC NYC Audience Award and drew positive reviews from outlets like The New York Times. According to Paramount+, critics called it urgent and illuminating.

How does Paramount+ (PSKY) position THE PINK PILL in relation to International Women’s Day?

Paramount+ positions the March 6 premiere as a timely release ahead of International Women’s Day on March 8. According to Paramount+, the timing aims to spark conversations about medical equity and women’s health.